124 related articles for article (PubMed ID: 38391191)
1. Effect of cyproterone acetate/ethinyl estradiol combination on periodontal status and high-sensitivity C-reactive protein levels in women with polycystic ovary syndrome: a cross-sectional study.
Singhal R; Tewari S; Sharma R; Singhal S; Tanwar N; Sangwan A
Quintessence Int; 2024 Apr; 55(4):274-285. PubMed ID: 38391191
[TBL] [Abstract][Full Text] [Related]
2. Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects.
Ruan X; Kubba A; Aguilar A; Mueck AO
Eur J Contracept Reprod Health Care; 2017 Jun; 22(3):183-190. PubMed ID: 28463030
[TBL] [Abstract][Full Text] [Related]
3. Impact of Polycystic Ovary Syndrome on Periodontal Status of Women of Adolescent and Adult Age Groups: A Cross-Sectional Study.
Jaglan S; Tewari S; Singhal SR; Sharma RK
Med Princ Pract; 2024; 33(2):148-156. PubMed ID: 38211576
[TBL] [Abstract][Full Text] [Related]
4. Effect of scaling on serum high-sensitivity C-reactive protein levels and periodontal parameters in systemically healthy women of reproductive age group with gingivitis.
Verma R; Tewari S; Anand D
Quintessence Int; 2024 Jun; 0(0):1-17. PubMed ID: 38847139
[TBL] [Abstract][Full Text] [Related]
5. Serum high-sensitivity C-reactive protein and homocysteine changes during hormonal therapy in women with polycystic ovary syndrome: a prospective, matched study.
Makedos A; Goulis DG; Papanikolaou A; Panidis D
Angiology; 2010 Aug; 61(6):595-601. PubMed ID: 20395229
[TBL] [Abstract][Full Text] [Related]
6. Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate.
Markantes G; Saltamavros AD; Vervita V; Armeni AK; Karela A; Adonakis G; Decavalas G; Georgopoulos NA
Gynecol Endocrinol; 2011 Dec; 27(12):971-7. PubMed ID: 21501001
[TBL] [Abstract][Full Text] [Related]
7. The influence of combined cyproterone acetate-ethinyl oestradiol therapy on serum levels of dehydroepiandrosterone, androstenedione, and testosterone in hirsute women.
Frölich M; Lachinsky N; Moolenaar AJ
Acta Endocrinol (Copenh); 1977 Feb; 84(2):333-42. PubMed ID: 138326
[TBL] [Abstract][Full Text] [Related]
8. How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?
Kabil Kucur S; Gozukara I; Aksoy A; Uludag EU; Keskin H; Kamalak Z; Carlioglu A
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):862-5. PubMed ID: 25402193
[TBL] [Abstract][Full Text] [Related]
9. A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome.
Mhao NS; Al-Hilli AS; Hadi NR; Jamil DA; Al-Aubaidy HA
Diabetes Metab Syndr; 2016; 10(1 Suppl 1):S95-8. PubMed ID: 26703220
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
Falsetti L; Galbignani E
Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631
[TBL] [Abstract][Full Text] [Related]
11. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate.
Armstrong VL; Wiggam MI; Ennis CN; Sheridan B; Traub AI; Atkinson AB; Bell PM
QJM; 2001 Jan; 94(1):31-7. PubMed ID: 11161134
[TBL] [Abstract][Full Text] [Related]
12. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
Falsetti L; Pasinetti E
Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
[TBL] [Abstract][Full Text] [Related]
13. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
Falsetti L; Dordoni D; Gastaldi C; Gastaldi A
Acta Eur Fertil; 1986; 17(1):19-25. PubMed ID: 2941960
[TBL] [Abstract][Full Text] [Related]
14. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
Leelaphiwat S; Jongwutiwes T; Lertvikool S; Tabcharoen C; Sukprasert M; Rattanasiri S; Weerakiet S
J Obstet Gynaecol Res; 2015 Mar; 41(3):402-10. PubMed ID: 25319761
[TBL] [Abstract][Full Text] [Related]
15. Effect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome.
Karakurt F; Carlioglu A; Kaygusuz I; Gumus II; Uz B; Akdeniz D
Arch Gynecol Obstet; 2014 Jan; 289(1):135-40. PubMed ID: 23880889
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives.
Porcile A; Gallardo E
Fertil Steril; 1991 May; 55(5):877-81. PubMed ID: 1827074
[TBL] [Abstract][Full Text] [Related]
17. [Inhibition of ovulation with 35 micrograms of ethinyl estradiol and 2 mg of cyproterone acetate (Diane 35)].
Spona J; Huber J; Schmidt JB
Geburtshilfe Frauenheilkd; 1986 Jul; 46(7):435-8. PubMed ID: 3093307
[TBL] [Abstract][Full Text] [Related]
18. The polycystic ovary syndrome presenting as resistant acne successfully treated with cyproterone acetate.
Eden JA
Med J Aust; 1991 Nov; 155(10):677-80. PubMed ID: 1834923
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and metabolic safety of long-term treatment with ethinyl oestradiol/cyproterone and desogestrel/ethinyl oestradiol tablets in women with polycystic ovary syndrome].
Zhang J; Su M; Xu L; Yang Z; Yin W; Nie Y; Qiao X; Cheng R; Ma Y
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jul; 38(8):917-922. PubMed ID: 30187872
[TBL] [Abstract][Full Text] [Related]
20. Cyproterone acetate for hirsutism.
Van der Spuy ZM; le Roux PA
Cochrane Database Syst Rev; 2003; 2003(4):CD001125. PubMed ID: 14583927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
